Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHMST3)

Drug Name
CCX915 Drug Info
Synonyms
Meglitinide; 54870-28-9; Meglitinide [INN]; Meglitinidum [INN-Latin]; Meglitinido [INN-Spanish]; HB 699; UNII-8V6OK1I088; BRN 2817215; 8V6OK1I088; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)benzoic acid; 4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)benzoasaeure [German]; p-(2-(5-Chloro-o-anisamido)ethyl)benzoic acid; C17H16ClNO4; 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid; Meglitinido; Meglitinidum; Benzoic acid, 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]-
Cross-matching ID
PubChem CID
41214
CAS Number
CAS 54870-28-9
TTD Drug ID
D0MT0A

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Cell cycle 1.90 4.40e-2 110/124 (88.71%) CDC20;MCM3;E2F2;...
Linoleic acid metabolism 1.78 4.67e-2 21/29 (72.41%) PLAAT3;CYP2C8;CYP1A2;...
Viral myocarditis -1.66 4.00e-2 53/60 (88.33%) DMD;ITGB2;ITGAL;...
Toxoplasmosis -1.67 3.83e-2 103/112 (91.96%) LAMA3;IL10RA;TYK2;...
Chagas disease -1.69 3.28e-2 93/102 (91.18%) PPP2R2B;CCL5;PIK3R1;...
Vibrio cholerae infection -1.71 3.06e-2 44/50 (88%) GNAS;KDELR2;ATP6V1A;...
Influenza A -1.73 2.88e-2 156/172 (90.7%) IL1A;CCL5;IRF3;...
Allograft rejection -1.75 2.68e-2 32/38 (84.21%) FAS;IL5;HLA-DOA;...
Collecting duct acid secretion -1.78 1.97e-2 22/27 (81.48%) CLCNKB;ATP6V1A;ATP6V0D1;...
Antigen processing and presentation -1.79 1.85e-2 60/78 (76.92%) HLA-DOA;IFI30;TAPBP;...
Phagosome -1.80 1.72e-2 118/152 (77.63%) CTSS;THBS1;ATP6V1A;...
Glycolysis / Gluconeogenesis -1.80 1.74e-2 56/67 (83.58%) PCK2;ALDOA;PCK1;...
Tuberculosis -1.86 1.06e-2 159/180 (88.33%) EEA1;ATP6V1H;IL1A;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.86 1.13e-2 79/89 (88.76%) CD3G;NRAS;RPS6KB2;...
Osteoclast differentiation -1.87 1.01e-2 117/127 (92.13%) ITGB3;SIRPB1;IL1A;...
Hematopoietic cell lineage -1.87 1.08e-2 90/99 (90.91%) CD3G;GP1BB;KITLG;...
T cell receptor signaling pathway -1.89 1.06e-2 93/104 (89.42%) MAPK10;GRB2;CD40LG;...
Pentose phosphate pathway -1.90 8.95e-3 25/30 (83.33%) DERA;PGLS;ALDOB;...
Th17 cell differentiation -1.91 8.44e-3 95/107 (88.79%) TYK2;CD247;TGFBR1;...
Graft-versus-host disease -1.93 7.82e-3 32/42 (76.19%) FAS;HLA-DOA;IFNG;...
Natural killer cell mediated cytotoxicity -1.95 8.79e-3 99/131 (75.57%) KLRC3;MAP2K2;ITGB2;...
Oxidative phosphorylation -1.96 6.03e-3 93/133 (69.92%) ATP6V1A;ATP6V1H;NDUFV1;...
Leishmaniasis -1.97 4.69e-3 67/77 (87.01%) STAT1;JAK2;HLA-DOA;...
Steroid biosynthesis -1.97 5.63e-3 19/20 (95%) EBP;LSS;DHCR7;...
Neutrophil extracellular trap formation -1.98 7.04e-3 101/189 (53.44%) MAP2K2;ITGB2;PIK3R1;...
Th1 and Th2 cell differentiation -1.98 9.38e-3 80/92 (86.96%) TYK2;CD247;STAT1;...
Thiamine metabolism -2.09 7.04e-3 12/15 (80%) TPK1;AK5;ACP1;...
Type I diabetes mellitus -2.17 1.41e-2 38/43 (88.37%) FAS;HLA-DOA;IFNG;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H